Analyst Bill Maughan works at CANACCORD and is covering the the Healthcare sector with 7 price targets and ratings documented since 2022 spanning on 4 stocks.
Most recent stock forecast was given on FATE, Fate Therapeutics, Inc at 11-Oct-2022.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS, INC).
Currently, out of the existing stock ratings of Bill Maughan - 2 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
17
$9.2 (117.95%)
17
7 days ago
0/3 (0%)
$12.43 (171.68%)
17
$9.2 (117.95%)
10 months 5 days ago
0/1 (0%)
$12.74 (299.06%)
Buy
20
$12.2 (156.41%)
24
1 years 1 months 20 days ago
0/2 (0%)
$9.05 (117.58%)
Buy
25
$17.2 (220.51%)
25
1 years 11 months 23 days ago
1/3 (33.33%)
$12.1 (114.56%)
245
Buy
23
$15.2 (194.87%)
2 years 4 months 26 days ago
1/1 (100%)
$5.89 (34.42%)
36
